The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study
{{output}}
Introduction: In mainland China, trastuzumab deruxtecan was first authorized in February 2023 as a monotherapy for the treatment of patients with HER-2-positive adult breast cancer who were either unresectable or had metastasized... ...
